CA2557538A1 - Derive du benzimidazole et son utilisation comme antagoniste du recepteur de l'angiotensine ii - Google Patents

Derive du benzimidazole et son utilisation comme antagoniste du recepteur de l'angiotensine ii Download PDF

Info

Publication number
CA2557538A1
CA2557538A1 CA002557538A CA2557538A CA2557538A1 CA 2557538 A1 CA2557538 A1 CA 2557538A1 CA 002557538 A CA002557538 A CA 002557538A CA 2557538 A CA2557538 A CA 2557538A CA 2557538 A1 CA2557538 A1 CA 2557538A1
Authority
CA
Canada
Prior art keywords
compound
methyl
oxo
mammal
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002557538A
Other languages
English (en)
Other versions
CA2557538C (fr
Inventor
Takanobu Kuroita
Hiroki Sakamoto
Mami Ojima
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34858222&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2557538(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2557538A1 publication Critical patent/CA2557538A1/fr
Application granted granted Critical
Publication of CA2557538C publication Critical patent/CA2557538C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyrrole Compounds (AREA)

Abstract

La présente invention concerne un composé représenté par la formule (I) dans laquelle R<SUP>1</SUP> est un groupe représenté par la formule dans laquelle R<SUP>2</SUP>, R<SUP>3</SUP>, R<SUP>4</SUP>, R<SUP>5</SUP>, R<SUP>6</SUP>, R<SUP>7</SUP> et R<SUP>8</SUP> sont chacun indépendamment un atome d'hydrogène ou un groupe alkyle en C<SUB>6-1</SUB>, ou un sel de celui-ci. Le composé de la présente invention est utile comme agent pour la prophylaxie ou le traitement de maladies circulatoires telles que l'hypertension et ses équivalents et de maladies métaboliques telles que le diabète et ses équivalents.
CA2557538A 2004-02-25 2005-02-23 Derive du benzimidazole et son utilisation comme antagoniste du recepteur de l'angiotensine ii Active CA2557538C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2004-048928 2004-02-25
JP2004048928 2004-02-25
US11/031,057 US7157584B2 (en) 2004-02-25 2005-01-07 Benzimidazole derivative and use thereof
US11/031,057 2005-01-07
PCT/JP2005/003422 WO2005080384A2 (fr) 2004-02-25 2005-02-23 Dérivé du benzimidazole et ses utilisations

Publications (2)

Publication Number Publication Date
CA2557538A1 true CA2557538A1 (fr) 2005-09-01
CA2557538C CA2557538C (fr) 2010-08-17

Family

ID=34858222

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2557538A Active CA2557538C (fr) 2004-02-25 2005-02-23 Derive du benzimidazole et son utilisation comme antagoniste du recepteur de l'angiotensine ii

Country Status (33)

Country Link
US (3) US7157584B2 (fr)
EP (3) EP2119715B1 (fr)
JP (2) JP4256852B2 (fr)
KR (1) KR101080029B1 (fr)
CN (2) CN101381366B (fr)
AR (2) AR047972A1 (fr)
AT (2) ATE370136T1 (fr)
AU (1) AU2005214271B8 (fr)
BR (2) BR122012009489B8 (fr)
CA (1) CA2557538C (fr)
CY (5) CY1107008T1 (fr)
DE (3) DE602005016162D1 (fr)
DK (3) DK1857457T3 (fr)
ES (3) ES2293552T3 (fr)
HK (2) HK1098472A1 (fr)
HR (3) HRP20070510T3 (fr)
HU (1) HUS1200008I1 (fr)
IL (1) IL177533A (fr)
LU (1) LU91962I2 (fr)
MA (1) MA28478B1 (fr)
ME (2) ME01089B (fr)
MY (1) MY142807A (fr)
NL (1) NL300802I2 (fr)
NO (2) NO332344B1 (fr)
NZ (1) NZ549755A (fr)
PL (3) PL2119715T3 (fr)
PT (3) PT1857457E (fr)
RS (3) RS51137B (fr)
RU (2) RU2369608C2 (fr)
SI (3) SI1857457T1 (fr)
TW (1) TWI336702B (fr)
WO (1) WO2005080384A2 (fr)
ZA (1) ZA200607241B (fr)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7157584B2 (en) * 2004-02-25 2007-01-02 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use thereof
US7795275B2 (en) 2004-12-24 2010-09-14 Uniquest Pty Limited Method of treatment or prophylaxis
JP4465469B2 (ja) * 2005-02-21 2010-05-19 国立大学法人佐賀大学 循環器病マーカーとしてのインターロイキン１３
CA2602624A1 (fr) * 2005-03-30 2006-10-12 Takeda Pharmaceutical Company Limited Derive de benzimidazole et utilisation de celui-ci
WO2007097452A1 (fr) * 2006-02-27 2007-08-30 Takeda Pharmaceutical Company Limited Emballage-coque à usage médical
US20090012132A1 (en) * 2006-02-27 2009-01-08 Takeda Pharmaceutical Company Limited Pharmaceutical Package
EP1996183A4 (fr) * 2006-03-20 2010-04-14 Spinifex Pharm Pty Ltd Méthode de traitement prophylactique ou thérapeutique
ES2381507T3 (es) * 2006-09-25 2012-05-28 Takeda Pharmaceutical Company Limited Envase medicinal
BRPI0809522A2 (pt) * 2007-03-28 2014-10-14 Takeda Pharmaceutical Composição farmacêutica sólida, métodos para estabilizar um composto, e para melhorar dissolução de um composto, e, uso de um agente de controle de ph.
JP2009062296A (ja) * 2007-09-05 2009-03-26 Fujifilm Corp カルボン酸エステル化合物の製造方法
JP5554699B2 (ja) * 2008-03-13 2014-07-23 第一三共株式会社 オルメサルタンメドキソミルを含む製剤の溶出性の改善
UY32017A (es) 2008-07-31 2010-02-26 Takeda Pharmaceutical Composición farmacéutica sólida
UY32126A (es) 2008-09-25 2010-04-30 Takeda Pharmaceutical Composición farmacéutica sólida
CN102264228A (zh) * 2008-10-22 2011-11-30 默沙东公司 用于抗糖尿病药的新的环状苯并咪唑衍生物
WO2010075347A2 (fr) 2008-12-23 2010-07-01 Takeda Pharmaceutical Company Limited Méthode de traitement de l'hypertension avec au moins un agent bloquant les récepteurs d'angiotensine ii et de la chlorthalidone
US20110009347A1 (en) * 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
KR101931209B1 (ko) 2010-05-11 2018-12-20 얀센 파마슈티카 엔.브이. Sglt의 억제제로서 1-(베타-d-글루코피라노실)-2-티에닐-메틸벤젠 유도체를 포함하는 약학 제형
WO2012090043A1 (fr) 2010-12-29 2012-07-05 Jubilant Life Sciences Limited Nouvelles formes à l'état solide d'azilsartan médoxomil et leur procédé de préparation
CA2824316C (fr) 2011-01-20 2020-07-07 Jiangsu Hansoh Pharmaceutical Co., Ltd. Sels d'amine organique d'azilsartan, leur procede de preparation et leur utilisation
EP2673274B1 (fr) 2011-02-08 2019-07-17 Jubilant Generics Limited Procédé amélioré pour la préparation d'azilsartan médoxomil
CN102138899B (zh) * 2011-03-18 2013-08-21 海南本创医药科技有限公司 阿齐沙坦酯脂质体固体制剂
AU2012241897C1 (en) 2011-04-13 2017-05-11 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of SGLT2
CN102827153B (zh) * 2011-06-14 2016-10-05 江苏豪森药业集团有限公司 阿齐沙坦的晶型及其制备方法
CN102351853B (zh) * 2011-08-29 2014-03-12 石药集团欧意药业有限公司 一种阿齐沙坦酯化合物、制备方法及其药物组合物
WO2013042067A1 (fr) 2011-09-20 2013-03-28 Ranbaxy Laboratories Limited Procédé de préparation d'un sel de potassium de l'azilsartan médoxomil
WO2013042066A1 (fr) 2011-09-20 2013-03-28 Ranbaxy Laboratories Limited Procédé de préparation d'azilsartan médoxomil
BR112014014527A2 (pt) 2011-12-15 2017-06-13 Takeda Pharmaceuticals Usa Inc combinações de azilsartan e clorotalidona para tratar hipertensão em pacientes negros
WO2013088384A2 (fr) 2011-12-15 2013-06-20 Jubilant Life Sciences Limited Formes à l'état solide d'azilsartan et d'azilsartan médoxomil monopotassique et leur procédé de préparation
US9403811B2 (en) 2012-01-14 2016-08-02 Sunshine Lake Pharma Co., Ltd. Crystalline forms of azilsartan medoxomil potassium and preparation and uses thereof
US20150011774A1 (en) * 2012-02-02 2015-01-08 Ranbaxy Laboratories Limited Process for the preparation of azilsartan medoxomil or pharmaceutically acceptable salts thereof
WO2013124748A1 (fr) * 2012-02-20 2013-08-29 Alembic Pharmaceuticals Limited Nouveaux polymorphes d'azilsartan médoxomil potassique
CZ2012274A3 (cs) * 2012-04-19 2013-10-30 Zentiva, K.S. Zpusob prípravy vysoce cisté draselné soli azilsartanu medoxomilu
WO2013186792A2 (fr) * 2012-06-11 2013-12-19 Msn Laboratories Limited Procédé de préparation de 2-éthoxy-1-{[2'-(5-oxo-4,5-dihydro-1,2,4- oxadiazol-3-yl)biphényl-4-yl]méthyl}-lh-benzimidazole-7-carboxylate de (5-méthyl-2-oxo-l,3-dioxol-4-yl)méthyle et de ses sels
EP2870151A4 (fr) * 2012-07-09 2016-03-23 Hetero Research Foundation Nouveaux polymorphes d'azilsartan
WO2014020381A1 (fr) * 2012-08-01 2014-02-06 Alembic Pharmaceuticals Limited Forme cristalline inédite d'azilsartan médoxomil potassique
CA2890961A1 (fr) 2012-08-27 2014-03-06 Hetero Research Foundation Nouveaux polymorphes de l'azilsartan medoxomil
WO2014049512A2 (fr) 2012-09-26 2014-04-03 Lupin Limited Nouveau procédé de préparation d'azilsartan médoxomil
CZ305318B6 (cs) * 2012-09-26 2015-07-29 Zentiva, K.S. Způsob přípravy vysoce čisté draselné soli azilsartanu medoxomilu
CN103709154B (zh) * 2012-09-28 2016-06-15 武汉朗来科技发展有限公司 苯并咪唑衍生物及其制备方法和医药用途
IN2015DN03074A (fr) * 2012-10-09 2015-10-02 Avery Dennison Corp
CN103910720A (zh) * 2013-01-07 2014-07-09 广东东阳光药业有限公司 阿齐沙坦酯的新晶型及其制备方法
CN105153141B (zh) * 2013-02-04 2018-09-25 武汉朗来科技发展有限公司 苯并咪唑衍生物及其制备方法和医药用途
JP6281735B2 (ja) * 2013-03-19 2018-02-21 トーアエイヨー株式会社 急性心不全治療薬の評価方法、及び、急性心不全モデルの作製方法
RU2535005C1 (ru) * 2013-06-11 2014-12-10 Николай Андреевич Козлов Способ лечения грыж межпозвонковых дисков у собак
RU2535004C1 (ru) * 2013-06-11 2014-12-10 Николай Андреевич Козлов Способ лечения грыж межпозвонковых дисков у собак
CN105949182B (zh) * 2013-10-12 2019-03-19 杭州领业医药科技有限公司 阿齐沙坦酯的晶型及其制备方法
CN104812752B (zh) * 2013-10-12 2016-09-28 杭州领业医药科技有限公司 阿齐沙坦酯的晶型及其制备方法
CN104774196B (zh) * 2014-01-09 2017-11-10 武汉朗来科技发展有限公司 一种苯并咪唑衍生物的制备方法
CN104774197B (zh) * 2014-01-09 2017-11-17 武汉朗来科技发展有限公司 一种苯并咪唑衍生物的制备方法
CN105079815A (zh) * 2014-04-30 2015-11-25 广东东阳光药业有限公司 一种阿齐沙坦酯钾组合物及其制备方法
CN104016974A (zh) * 2014-06-24 2014-09-03 浙江天宇药业股份有限公司 阿齐沙坦酯中间体及其合成方法、阿齐沙坦酯的合成方法
CZ2014702A3 (cs) 2014-10-15 2016-04-27 Zentiva, K.S. Způsob přípravy vysoce čistého azilsartanu
CN105622595A (zh) * 2014-11-21 2016-06-01 重庆朗天制药有限公司 一种阿奇沙坦酯钾盐及其中间体新的制备方法
CN105753854A (zh) * 2014-12-16 2016-07-13 重庆朗天制药有限公司 一种阿齐沙坦酯钾盐的新制备方法
WO2016145622A1 (fr) 2015-03-18 2016-09-22 武汉朗来科技发展有限公司 Dérivés de benzimidazole, leur procédé de préparation et leur utilisation médicinale
CN106032378B (zh) * 2015-03-20 2019-10-25 武汉启瑞药业有限公司 新型arb化合物及其用途
CN104803998B (zh) * 2015-03-26 2017-08-25 晋江市托美汀生物科技有限公司 一种降低杂质含量的方法
JP2018521077A (ja) * 2015-07-29 2018-08-02 タケダ ゲー・エム・ベー・ハーＴａｋｅｄａ ＧｍｂＨ 糖尿病性腎症を治療するためのｐｄｅ４阻害剤
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
CN109071519A (zh) * 2016-01-28 2018-12-21 株式会社德山 阿齐沙坦及其制造方法
JP6856365B2 (ja) * 2016-11-30 2021-04-07 株式会社トクヤマ アジルサルタンの製造方法
CN105628824B (zh) * 2016-03-06 2017-10-17 江苏正大清江制药有限公司 一种高效液相色谱法测定阿齐沙坦原料中有关物质的方法
CN107400122B (zh) 2016-05-20 2020-10-23 武汉朗来科技发展有限公司 化合物及其制备方法、组合物和应用
CN105770876B (zh) * 2016-05-30 2019-09-10 广东天普生化医药股份有限公司 乌司他丁在制备治疗慢性前列腺炎药物中的用途
RU2623082C1 (ru) * 2016-07-11 2017-06-21 Государственное бюджетное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ коррекции артериальной ригидности у больных ревматоидным артритом
EP3461822B1 (fr) * 2016-07-11 2022-11-02 Wuhan LL Science And Technology Development Co., Ltd. Forme cristalline de composé chimique, son procédé de préparation, sa composition et son application
RU2634272C1 (ru) * 2016-08-10 2017-10-24 Закрытое акционерное общество "Санкт-Петербургский институт фармации" Композиция с дезамино-аргинин-вазотоцином для парентерального введения и способ её получения
CN106074416A (zh) * 2016-08-30 2016-11-09 佛山市弘泰药物研发有限公司 一种阿齐沙坦酯钾盐分散片的制备方法
CN109803657B (zh) * 2016-10-08 2022-07-29 武汉朗来科技发展有限公司 药物组合物
WO2019130277A1 (fr) 2017-12-30 2019-07-04 Lupin Limited Formulations pharmaceutiques d'azilsartan médoxomil
CN110237071B (zh) * 2018-03-09 2022-03-22 武汉朗来科技发展有限公司 药物制剂及其应用
CN110237072B (zh) * 2018-03-09 2022-03-25 武汉朗来科技发展有限公司 药物组合物的制备方法
CN117542473A (zh) 2018-06-14 2024-02-09 阿斯利康(英国)有限公司 用血管紧张素ii受体阻滞剂医药组合物治疗高血压的方法
US11417416B2 (en) * 2018-06-14 2022-08-16 Astrazeneca Uk Limited Methods for lowering blood pressure with a dihydropyridine-type calcium channel blocker pharmaceutical composition
WO2020101450A1 (fr) 2018-11-16 2020-05-22 엠에프씨 주식회사 Composés dérivés d'azilsartan, leurs intermédiaires, leur procédé de préparation et composition pharmaceutique les comprenant
JPWO2020166710A1 (ja) 2019-02-15 2021-12-16 国立大学法人東北大学 １，３−ジオキソラン誘導体
KR102220011B1 (ko) 2020-05-15 2021-02-25 대봉엘에스 주식회사 친환경 용매를 이용한 아질사탄의 제조방법 및 이에 관한 핵심 중간체 화합물
CN113912580B (zh) * 2021-11-03 2023-06-02 瑞孚信江苏药业股份有限公司 一种纯化4-(羟甲基)-5-甲基-[1,3]二氧杂环戊烯-2-酮的方法
CA3231724A1 (fr) 2021-12-28 2023-07-06 Alchemedicine, Inc. Compose, antagoniste du recepteur de l'angiotensine ii de type 1 et composition pharmaceutique
KR20240039252A (ko) 2022-09-19 2024-03-26 대봉엘에스 주식회사 안지오텐신 ⅱ 길항제로서의 아질사르탄 디시클로헥실아민 및 이를 유효성분으로 하는 심혈관질환 치료 또는 예방용 약학적 조성물

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62290071A (ja) 1986-06-09 1987-12-16 Matsushita Electric Ind Co Ltd 有機電解質二次電池
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5616599A (en) 1991-02-21 1997-04-01 Sankyo Company, Limited Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
IS1756B (is) 1991-02-21 2000-12-28 Sankyo Company Limited Hliðstæðuaðferð til framleiðslu 1-Biphenylmethylimidazole afleiða
IL102183A (en) 1991-06-27 1999-11-30 Takeda Chemical Industries Ltd The heterocyclic compounds are converted into biphenyl groups, their production and the pharmaceutical compositions containing them
RU2117668C1 (ru) * 1991-10-23 1998-08-20 Эйсаи Ко., Лтд. Производное оксазолидона или его фармакологически приемлемые соли, фармацевтическая композиция, способ лечения
US5310929A (en) 1992-08-06 1994-05-10 E. I. Du Pont De Nemours And Company Prodrugs of imidazole carboxylic acids as angiotensin II receptor antagonists
US5605919A (en) * 1993-02-26 1997-02-25 Takeda Chemical Industries, Ltd. Treatment for viral diseases
TW403748B (en) * 1994-11-02 2000-09-01 Takeda Chemical Industries Ltd An oxazolidinedione derivative, its production and a pharmaceutical composition for lowering blood sugar and lipid in blood comprising the same
US5610314A (en) 1995-04-03 1997-03-11 Bristol-Myers Squibb Company Process for preparing dioxolenone derivatives used for making prodrug esters and intermediates
KR100866820B1 (ko) 2000-07-13 2008-11-04 다케다 야쿠힌 고교 가부시키가이샤 지질 풍부 플라크 퇴축제
AU2002349673A1 (en) 2001-12-03 2003-06-17 Takeda Chemical Industries, Ltd. Insulin resistance improving agents
KR20040081123A (ko) 2002-01-11 2004-09-20 다케다 야쿠힌 고교 가부시키가이샤 쿠마린 유도체, 이의 제조 방법 및 용도
CA2507026A1 (fr) 2002-11-22 2004-06-10 Takeda Pharmaceutical Company Limited Derives d'imidazole, leur procede de production et d'utilisation
US6972258B2 (en) * 2003-08-04 2005-12-06 Taiwan Semiconductor Manufacturing Co., Ltd. Method for selectively controlling damascene CD bias
US7157584B2 (en) * 2004-02-25 2007-01-02 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use thereof
JP4364171B2 (ja) 2005-07-15 2009-11-11 本田技研工業株式会社 自動車用ドアチェッカ
UA58542U (ru) * 2010-12-16 2011-04-11 Леонид Борисович Борейко Способ фиксирования эвакуационной машины во время вытягивания застрявшей тяжелой машины

Also Published As

Publication number Publication date
CY2012015I2 (el) 2016-12-14
US7572920B2 (en) 2009-08-11
MY142807A (en) 2011-01-14
RU2009115498A (ru) 2010-10-27
LU91962I2 (fr) 2012-05-21
EP1718641A2 (fr) 2006-11-08
IL177533A0 (en) 2006-12-10
WO2005080384A2 (fr) 2005-09-01
EP1718641B1 (fr) 2007-08-15
CN1946717A (zh) 2007-04-11
HRP20070510T3 (en) 2007-12-31
CN101381366A (zh) 2009-03-11
PL1857457T3 (pl) 2009-12-31
CY1107008T1 (el) 2012-09-26
NZ549755A (en) 2009-04-30
RS50537B (sr) 2010-05-07
AU2005214271B8 (en) 2011-03-03
AR094588A2 (es) 2015-08-12
MA28478B1 (fr) 2007-03-01
BRPI0507984B8 (pt) 2023-03-21
RU2501798C2 (ru) 2013-12-20
SI1857457T1 (sl) 2010-01-29
CY2012016I1 (el) 2016-12-14
TW200530227A (en) 2005-09-16
ES2293552T3 (es) 2008-03-16
CY1109610T1 (el) 2014-08-13
ME01643B (fr) 2010-05-07
CY2012015I1 (el) 2016-12-14
HRP20090593T1 (hr) 2010-03-31
CN101381366B (zh) 2011-06-15
CY2012016I2 (el) 2016-12-14
ES2331209T3 (es) 2009-12-23
TWI336702B (en) 2011-02-01
PL2119715T3 (pl) 2012-10-31
DE602005002030D1 (de) 2007-09-27
RU2369608C2 (ru) 2009-10-10
WO2005080384A3 (fr) 2006-09-28
JP2005272451A (ja) 2005-10-06
EP2119715B1 (fr) 2012-05-30
PT1718641E (pt) 2007-11-15
NO332344B1 (no) 2012-09-03
HUS1200008I1 (hu) 2017-06-28
BR122012009489B8 (pt) 2023-03-21
PL1718641T3 (pl) 2008-01-31
US7157584B2 (en) 2007-01-02
AU2005214271A2 (en) 2005-09-01
HK1098472A1 (en) 2007-07-20
DE602005016162D1 (de) 2009-10-01
SI2119715T1 (sl) 2012-10-30
AU2005214271B2 (en) 2011-02-24
JP4256852B2 (ja) 2009-04-22
HRP20120667T2 (hr) 2012-11-30
ES2388945T3 (es) 2012-10-22
EP2119715A1 (fr) 2009-11-18
HK1115118A1 (en) 2008-11-21
US20050187269A1 (en) 2005-08-25
BRPI0507984B1 (pt) 2018-07-03
HRP20120667T1 (en) 2012-09-30
RS51137B (sr) 2010-10-31
DE122012000018I1 (de) 2012-06-06
EP1857457A3 (fr) 2007-12-05
DK1718641T3 (da) 2007-12-17
ATE370136T1 (de) 2007-09-15
BR122012009489B1 (pt) 2019-02-19
NO2012017I2 (no) 2012-11-09
WO2005080384A9 (fr) 2006-11-30
DE602005002030T2 (de) 2008-05-08
US20060281795A1 (en) 2006-12-14
RS52376B (en) 2012-12-31
US7875637B2 (en) 2011-01-25
JP2009137974A (ja) 2009-06-25
KR20070020411A (ko) 2007-02-21
CN100503605C (zh) 2009-06-24
NO20064251L (no) 2006-11-22
ME01089B (me) 2013-03-20
ATE440095T1 (de) 2009-09-15
NL300802I2 (fr) 2016-05-18
NO2012017I1 (no) 2012-11-26
SI1718641T1 (sl) 2007-12-31
IL177533A (en) 2010-12-30
BRPI0507984A (pt) 2007-07-24
EP1857457B1 (fr) 2009-08-19
PT1857457E (pt) 2009-09-23
DK1857457T3 (da) 2009-12-21
RU2006133898A (ru) 2008-03-27
DK2119715T3 (da) 2012-09-10
EP1857457A2 (fr) 2007-11-21
CY1113084T1 (el) 2016-04-13
PT2119715E (pt) 2012-09-03
AU2005214271A1 (en) 2005-09-01
KR101080029B1 (ko) 2011-11-04
ZA200607241B (en) 2008-04-30
US20090270464A1 (en) 2009-10-29
CA2557538C (fr) 2010-08-17
AR047972A1 (es) 2006-03-15

Similar Documents

Publication Publication Date Title
CA2557538A1 (fr) Derive du benzimidazole et son utilisation comme antagoniste du recepteur de l&#39;angiotensine ii
CA2643005A1 (fr) Derives d&#39;acide imidazol-5-carboxylique, leurs procedes de preparation et leur utilisation
RU2007139928A (ru) Производное бензимидазола и применение в качестве антагониста ангиотензина
RU2488582C2 (ru) Бициклозамещенные азопроизводные пиразолона, способ их получения и фармацевтическое применение
CA2565813A1 (fr) Composes methylaryl- ou heteroarylamides substitues
JP2007517044A5 (fr)
SU1637663A3 (ru) Способ получени производных 1-алкилзамещенных бензимидазолов
JP2008525416A5 (fr)
JP2005508967A5 (fr)
JP2012528166A5 (fr)
JP2011500659A5 (fr)
JP2002535323A5 (fr)
JPH06503834A (ja) アンジオテンシン２受容体遮断組成物
JP2012523457A5 (fr)
RU2007130144A (ru) Гетероциклические соединения в качестве антагонистов cccr2b
JP2006502143A5 (fr)
JP2007517035A5 (fr)
JP2011006480A5 (fr)
RU2013107007A (ru) Бифункциональные соединения, являющиеся ингибиторами rho-киназы, композиция и применение
CA2409741A1 (fr) Inhibiteurs de production de tnf-.alpha.
SK13195A3 (en) Imidazole carboxylic acids and pharmaceutical agent containing thereof
JP2008520605A5 (fr)
RU2005107589A (ru) Антидепрессанты-азагетероциклилметильные производные конденсированных с гетероциклами бензодиоксанов
WO1995026724A1 (fr) Amelioration de la sensibilite insulinique a l&#39;aide d&#39;imidazoles de blocage des recepteurs d&#39;angiotensine ii
JP2012510957A5 (fr)

Legal Events

Date Code Title Description
EEER Examination request